posted on Tuesday, 16th June 2020
Not tagged.
Permalink
In March 2020 there were reports which indicated a possible link
with taking non-steroidal anti-inflammatory drugs (NSAIDs), which
include ibuprofen and aspirin, and the severity of Covid-19.
However experts from the Commission of Human Medicine issued a
statement in April 2020, advising that there is currently
insufficient evidence to establish a link between the use of
ibuprofen, or other nonsteroidal anti-inflammatory drugs (NSAIDs),
and contracting or worsening of COVID19. There are now
Covid-19 trials taking place with aspirin as a treatment, as it is
now known that excessive clotting is part of Covid-19.
If you develop coronavirus symptoms, check with your doctor for
advice on pain relief.
posted on Monday, 15th June 2020
Not tagged.
Permalink
The CAPP2 long term follow up paper is now published
The Lancet. DOI: 10.1016/S0140-6736(20)30366-4
The take home message is that the cancer chemopreventive effect
is even clearer than in the 2011 CAPP2 publication.
The protective effect of aspirin (600mg, 2 large tablets)
against colorectal cancer has persisted in this long-term follow up
of the CAPP2 trial, for up to 20 years.
Thank you to all the CAPP2 study participants and to the study
participants in the ongoing CaPP3 trial, which is looking to see
whether smaller doses of aspirin can be used to reduce the risk of
cancer in Lynch syndrome.
Further information about the CAPP2 Lancet paper is in the CaPPtain's
blog